TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
Subcutaneous Therapy
Advertisement
TREMFYA® Receives FDA Approval for Subcutaneous Induction in UC
HORSHAM, Pa., Sept. 19, 2025 — Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug...
Advertisement
